|Dr. Michael D. West Ph.D.||Co-Chief Exec. Officer, Pres and Director||758.57k||N/A||64|
|Mr. Aditya P. Mohanty||Co-Chief Exec. Officer and Director||763.25k||N/A||50|
|Mr. Russell L. Skibsted||Chief Financial Officer||493.25k||N/A||58|
|Ms. Judith Segall||VP of Admin. and Sec.||N/A||N/A||64|
|Mr. Dan L. Lawrence||Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. Its product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. The company also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products. Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia. BioTime, Inc. was founded in 1990 and is based in Alameda, California.
BioTime, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 5. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 5; Compensation: 6.